News and Announcements
Actinogen Medical Ltd (ASX: ACW) Alzheimer’s Treatment Receives Final Market Patent
- Published October 25, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Canadian Intellectual Property Office approved another major patent for Xanamem, Actinogen Medical Limited (ASX: ACW) breakthrough Alzheimer’s treatment
- Xanamem now holds a patent in over 80% of Alzheimer’s market worldwide including Japan, European Union, United Kingdom, China, United States and Australia
Actinogen Medical Limited (ASX: ACW) announced that the Canadian Intellectual Property Office has approved a patent for Xanamem in Canada for a period up to 2031. This means Xanamem now has patents in all major markets in the world including Japan, European Union, United Kingdom, China, United States and Australia. These countries represent more than 80% of Alzheimer’s market worldwide.
Xanamem, which was discovered by Dr Scott Webster and Professor Brian Walker, was developed as a treatment for Alzheimer’s diseases. Scientists believe that increased cortisol levels in the blood lead to the disease. Xanamem aims to reduce the harmful effects of the disease by blocking the production of cortisol.
The hypothesis that increased cortisol levels cause Alzheimer’s disease is supported by the Australian Imaging, Biomarker & Lifestyle Study of Ageing (AIBL) study. The authors agreed that Alzheimer’s diseases could be prevented by lowering the levels of cortisol.
The patent for Xanamem, however, covers not only Alzheimer’s diseases but a wide array of metabolic and neurological diseases. It also includes a patent for Xanamem’s composition. Those in the pharmaceutical industry usually seek patents for compositions and compounds as well as exclusive rights to the concerned drugs and this is the patent awarded to Xanamem.
“The strength of the Xanamem IP we are developing is reaffirmed with the grant of patents in these key countries. Xanamem is now patent protected in more than 80% of the global Alzheimer’s market, signalling the significant value of the Xanamem IP that we hope to commercialise in the future.” Actinogen Medical CEO and Managing Director Dr Bill Ketelbey said.
Actinogen Limited, now known as Ectinogen Medical Limited, specialises in the treatment of mild cognitive impairment and the more serious dementia and Alzheimer’s disease. The company is developing Xanamem, a drug that aims to treat not only Alzheimer’s but also neurodegenerative diseases related to age.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
